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Abstract 
Liver uptake of liposomes containing phosphatidylserine was studied in a single pass liver perfusion system and found to be serum 
dependent. The effectiveness of serum in mediating liposome uptake by the liver depends on liposome size. Large liposomes appeared to 
be opsonized more efficiently and, therefore, taken up more by the liver than the smaller ones. The effects of liposome size on liver 
uptake did not occur in the absence of serum. Treatment of serum at 56” C for 30 min abolished the serum activity, suggesting the 
involvement of complement components. Inhibition of the hemolytic activity of complement through the alternative pathway by 
PS-containing liposomes suggests that components in this pathway are responsible for liposome opsonization. Liposomes containing 
phosphatidic acid, phosphatidylglycerol, and dicetyl phosphate compete in different degrees for serum components which mediate the 
liver uptake of PS-containing liposomes. These results suggest that the opsonization of liposomes by serum opsonins are the determining 
factors for the recognition and clearance of liposomes by the RES. Complement components are most likely involved in this process. The 
results presented here are relevant to the use of liposomes as drug delivery vehicle in vivo and to the PS-mediated clearance of red blood 
cells from the blood circulation. 
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1. Introduction 
Liposomes, serving as both a model membrane and a 
drug carrier, have been intensively studied in the past 
thirty years ([1,2] for review). Among the many aspects of 
liposome research, interaction of liposomes with 
macrophages of the reticuloendothelial system (RES), par- 
ticularly those in the liver and spleen have drawn much 
attention [3-81. Generally, systematically administered li- 
posomes are rapidly taken up by the RES. The rate of 
clearance of injected liposomes from the blood circulation 
depends on liposome composition and size [6-81. It has 
been found that presence of phosphatidylserine (PS) in the 
liposome membrane, regardless of the matrix lipids 
[7,9,10], results in a rapid removal of the liposomes from 
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the blood and their accumulation in the liver and spleen. 
The effect of PS on liposome uptake by the RES can not 
be overcome by inclusion of ganglioside GM, into lipo- 
somes. GM, has been shown to possess the activity in 
decreasing liposome affinity for the RES and prolonging 
their circulation time in mice [9,10]. This observation is 
related to the physiological function of PS as a signal for 
triggering the recognition of sickled red blood cells (RBC) 
by macrophages [ll]. Under physiological conditions, PS 
is localized exclusively in the inner leaflet of the cell 
membrane [12]. The exposure of PS as occurs in activated 
platelets and sickled RBC leads to their recognition and 
removal from the blood circulation by mononuclear phago- 
cytes [ll-131. 
Clearly, PS plays a pivotal role in directing vesicles or 
cells to the RES. However, the mechanism responsible for 
such activity remains unknown. Evidence suggests that PS 
may serve as a signal that is directly recognized by 
macrophages. For example, it has been shown that inser- 
tion of a PS analog (NBD-PS) into mouse or human RBC 
membranes stimulates their binding and concomitant 
phagocytosis by cultured syngenic macrophages and allo- 
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genie monocytes [14]. Similar results have also been re- mixture was then perfused via the portal vein through the 
ported for PS-containing liposomes in studies using puri- liver of an anaesthetized rat (using diethyl ether vapor) at a 
fied macrophages [ 151 and established cell lines [ 161. How- rate of 7 ml/min. The inferior vena cava was cut at the 
ever, it is not clear if this is the case in vivo, because the beginning of perfusion to allow the perfusion solution to 
macrophages used in vitro may not have the same func- drain. The perfused liver was then washed with 50 ml of 
tional activity as those in liver and spleen. More impor- saline at the same perfusion rate. The amount of liposomes 
tantly, the role of blood components in PS-mediated lipo- taken up by the liver was determined by the ‘rlIn radioac- 
some or cell uptake by the RES has not been carefully tivity in the liver and was expressed as the percentage of 
examined. perfused dose. 
In this study, PS-containing liposomes were used as a 
model to demonstrate that the recognition of PS by the 
liver macrophages is mediated by serum components. It 
was shown that PS-containing liposomes can not be recog- 
nized by liver macrophages in the absence of serum. 
Complement components involved in the alternative path- 
way appeared to serve as opsonins that mediate the recog- 
nition and phagocytosis of PS-containing membrane vesi- 
cles by macrophages. 
2.4. Inhibition of hemolytic activity of complement by 
PS-containing liposomes 
2. Materials and methods 
2.1. Materials 
Egg phosphatidylcholine (PC), bovine brain phospha- 
tidylserine (PS), dipalmitoylphosphatidylglycerol (DPPG), 
and egg phosphatidic aci’d (PA) were purchased from 
Avanti Polar Lipids (Birmingham, AL); dicetyl phosphate 
(DCP), and cholesterol (Chol) were purchased from Sigma 
(St. Louis, MO). “‘In-diethylenetriamine pentaacetic acid 
distearylamine complex ( I1 ’ In-DTPA-SA) was prepared as 
described previously [7]. Rabbit whole blood in Alsever’s 
solution was purchased from Pel Freez Biologicals (Rogers, 
AR). Animals used were from Harlan Sprague Dawley 
(Indianapolis, IN). 
Liposomes (0.1 ml containing different amounts of 
lipids) were incubated with 0.2 ml of freshly collected rat 
serum for 30 min at 37” C in the presence of EGTA and 
Mg2+ which were kept at a final concentration of 7.5 mM, 
respectively. Liposome-treated serum (0.15 ml) was then 
diluted with PBS to 0.3 ml. Rabbit erythrocytes (0.1 ml, 
2. lo* cells/ml) were then added and the mixture was 
further incubated for 30 min at 37” C. The reaction was 
stopped by the addition of 1.6 ml of cold PBS containing 
EDTA (10 mM) and the mixture was then centrifuged at 
2500 X g for 10 min to remove the cells. The extent of 
hemolysis was measured spectrophotometrically at a wave- 
length of 413 nm. 
3. Results 
3.1. Uptake of PS-containing liposomes by perfused liver 
2.2. Liposome preparations 
Liposomes composed of PC/Chol/X (X represents the 
negatively charged phospholipids) with a molar ratio of 
10:5:1 were prepared by extrusion [7]. Briefly, lipids with 
a trace amount of “‘InDTPA-SA were mixed and dried 
under N, gas. The dried lipid film was then vacuum 
desiccated for at least 30 min to remove the residual 
organic solvent before it was hydrated in PBS (pH 7.4) 
overnight at room temperature. The lipid suspension was 
then extruded 20 times through two layers of polycarbon- 
ate filters (Nucleopore) with defined pore sizes by using 
LiposoFast extruder (Avestin, Ottawa, Canada)). The aver- 
age diameter of liposomes were measured by a submicron 
particle analyzer (Coulter N4SD). 
2.3. In situ liver perfusion 
Liposomes (0.6 pmol total lipids in 60 ~1) were added 
to 24 ml of saline or saline containing different amounts of 
serum and incubated for 10 minutes at 37” C. 20 ml of the 
To examine the uptake of PS-containing liposomes by 
the RES, we used a well developed rat liver perfusion 
model system [17,18]. PS-containing liposomes with dif- 
ferent diameters were incubated with saline, saline contain- 
ing 33% freshly collected serum or saline containing 66% 
blood (the final concentration of serum is about 33% 
assuming blood cells contribute 50% of the blood volume). 
After 10 min, the mixture was perfused through the liver 
via the portal vein. At the beginning of the perfusion, 
blood in liver circulation was released by cutting the 
inferior vena cava. Liposome uptake by the perfused liver 
in the presence or absence of blood components was 
compared. As shown in Fig. 1, there is a minimal level of 
liposome uptake by the liver in the absence of blood 
components. An approximate 5-fold increase in liposome 
uptake in comparison to the basal level obtained in the 
absence of blood components was observed for liposomes 
(d = 110 nm) preincubated with either 33% serum or 66% 
whole blood, indicating that serum components, but not 
the blood cells, are responsible for the increased liposome 
uptake by the liver. It was also noted that serum compo- 
nent-enhanced liposome uptake by the liver was further 
enhanced for liposomes with larger diameters. For exam- 
ple, about a lo-fold increase in uptake by the liver was 
obtained for liposomes with an average diameter of 410 
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nm as compared to that of basal level. Again, liposome 
uptake in the presence of 66% blood and 33% serum in 
saline showed little difference. Saline or saline presatu- 
rated with oxygen CO,, 95%, CO,, 5%) or Krebs-Henseleit 
buffer (pH 7.4) solution gave similar results (data not 
shown). 
To confirm our observation that the serum enhanced 
uptake of liposomes is not due to artifacts introduced in 
our perfusion system, we infused the same amount of 
liposomes via the portal vein (0.6 pmol in 1 ml) into live 
animals in a period of 3 min (the same time period used 
for the perfusion study). After infusion, an incision was 
made at the inferior vena cava and the liver was washed 
with 50 ml of saline via portal vein to remove unbound 
liposomes in the liver. Liposome uptake by the liver was 
then quantitated by ‘*‘In radioactivity detected in the liver. 
It is obvious from Fig. 1 that the amount of liposomes 
taken up by the liver under these conditions is also depen- 
dent on liposome size. Thus, the larger the diameter of 
liposomes, the more liposomes were taken up by the liver. 
3.2. Effect of serum concentration on liposome uptake 
To examine the effect of serum concentration on the 
amount of liposome uptake by the perfused liver, a fixed 
50 - 
r. 





loo 150 200 250 300 350 400 450 
LIPOSOME DIAMETER (m) 
Fig. 1. Effect of blood components on liver uptake of PS-containing 
liposomes with different diameters. Liposomes (PC/Chol/PS = l&5:1, 
molar ratio) containing 0.6 pmol total lipids were incubated with 24 ml 
of saline (O), saline containing 33% serum (H ) or containing 66% whole 
blood (0) (heparin as anticoagulant) for 10 min at 37” C, respectively. 20 
ml of mixed solution (0.5 pmol total lipids) was then perfused via the 
portal vein through the liver of a rat under anesthetization. The perfusion 
rate was about 7 ml/min. For infusion experiments (01, liposomes (0.5 
pmol total lipids in 1 ml of saline) were directly infused to the anes- 
thetized animals via the portal vein at the rate of 0.33 ml/min. At the end 
of the infusion, the blood circulation was broken by breaking the inferior 
vena cava. The liver was then washed with 50 ml of saline to remove 
unbound liposomes. The percentage of liposome uptake by the liver was 
analyzed by the amount of liposome accumulated in the liver divided by 
the total amount either perfused or infused. 
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Fig. 2. Effect of the amount of serum on liposome uptake by the perfused 
liver. (A) Liposomes (0.6 pmol total lipids in 60 ~1, d = 410 nm) were 
added to and then incubated with saline (24 ml total volume) or saline 
containing different amounts of serum for 10 min at 37” C before 
perfusion. (B) Same amount of liposomes as in A were directly added to 
different amounts of serum and incubated for 10 min at 3P C. The 
mixture was then diluted to a total volume of 24 ml by saline followed by 
perfusion. The conditions for perfusion and the data analysis are the same 
as those described in Fig. 1. 
Of 
amount of liposomes (0.6 pmol total lipids) was incubated 
with different amounts of serum and the total liposome 
uptake examined. Fig. 2A shows that liver uptake of 
liposomes increased with increasing amounts of serum (up 
to 33%). Further increase of the serum concentration re- 
sulted in a decrease of liposome uptake by the perfused 
liver. 
In an separate set of experiments, liposomes were first 
incubated with serum and then diluted to the final volume 
of perfusate. As is shown in Fig. 2B, direct incubation of 
liposomes with serum results in more efficient liposome 
opsonization. For example, incubation of liposomes with 
0.5 ml of serum directly is sufficient to produce about a 
40% uptake while it requires about 8 ml of serum to reach 
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the similar level of uptake if incubation was carried out 
with diluted serum (0.6 pm01 lipids, 16 ml saline and 8 ml 
serum). Again, with highe,r amounts of serum, liposome 
uptake by the perfused liver decreased. Human and bovine 
serum showed similar activity in mediating liver uptake of 
PS-containing liposomes (data not shown). 
3.3. Liposome uptake is mediated by complement 
Based on the results shown in Figs. 1 and 2, the obvious 
question one would ask is that what are the specific serum 
components (opsonins) responsible for the liposome up- 
take? Among the many possibilities, we tested the possible 
involvement of complement in liposome uptake. As shown 
in Table 1, treatment of serum at 56” C for 30 min to 
inactivate complement abolished the serum activity in 
mediating the liver uptake of liposomes. Dialysis of serum 
against saline (molecular mass cut off of the membrane is 
12-14 kDa) removes about 40% of the serum activity, 
suggesting that small molecules in serum with molecular 
mass less than 12-14 kDla play some role in mediating 
liposome uptake by the liver. 
If complement components serve as opsonins for PS- 
containing liposomes, we reasoned that serum complement 
activity should be consumed upon incubation with lipo- 
somes. To test this possibility, we examined the inhibitory 
effect of PS-containing liposomes on the hemolysis of 
erythrocytes by the alternative complement pathway. The 
results of this experiment (Fig. 3) showed that larger 
liposomes are more active than smaller ones in reducing 
the complement activity and, therefore, are more effective 
in inhibiting complement-mediated hemolysis. For exam- 
ple, about 95% of the lytic activity was inhibited at a 
liposome concentration of 0.5 mM for liposomes in a 
diameter of 570 nm in comparison to less than 20% 
inhibition for those with an average diameter of 103 nm. 
These results agree well with the conclusion drawn from 
the data in Table 1 and suggest that complement compo- 
nents serve as opsonins for the uptake of PS-containing 
Table 1 
Effect of serum treatments on serum mediated uptake of liposomes by 
liver 
Treatment % Uptake % Inhibition 
No treatment 32.9 (l.2) 0 
56” C, 30 min 3.6 0.2) 98.0 
Dialysis 21.8 (‘1.7) 37.1 
8 ml of rat serum was treated at 56’C for 30 min or dialyzed against 
saline (3 X 4 1 of saline at 4” C for 12 h). PS-containing liposomes (0.6 
Fmol total lipids in 60 ~1, d = 410 nm) were then incubated with 24 ml 
of saline containing 8 ml of serum with or without treatment for 10 min 
at 37” C. Perfusion was then performed as described in Materials and 
methods. The percent of inhibition by the various treatments was calcu- 
lated by dividing the total uptake of liposomes using treated serum by the 
total liposome uptake using serum without treatment. Data represent an 
average (SD.) of 2-4 individual experiments. 
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Fig. 3. Liposome size dependent inhibition of hemolytic activity of 
complement. PS-containing liposomes with an average diameter of 103 
nm or 570 nm were incubated with rat serum for 30 min at 37” C. The 
hemolytic activity of rat serum preincubated with different amounts of 
liposomes against rabbit red blood cells was measured as described in 
Materials and methods. Liposomes with diameter of 103 nm (0) and 570 
nm (0). 
liposomes. Also, opsonization activity 
varies with the diameter of liposomes. 
of complement 
3.4. Effect of preincubation of other negatively charged 
liposomes with serum on serum-mediated liver uptake of 
PS-containing liposomes 
It is well known that liposomes containing negatively 
charged lipids, such as PS, phosphatidic acid (PA), phos- 
phatidylglycerol (PG) and DCP show high affinity for the 
RES [5]. To examine whether such high affinity for the 
RES is mediated by the same opsonins in all cases. we 
preincubated serum with liposomes containing various 
negatively charged lipids and then determined the liver 
uptake of PS-containing liposomes (testing liposomes) in 
the presence of the treated-serum. Thus, 1 ml of bovine 
serum was incubated with different types of liposomes (2 
pmol total lipids in 0.2 ml) at 37” C for 10 min and 
liposomes removed by centrifugation (microfuge, max. 
speed, 10 min). To ensure that the liposomes were com- 
pletely removed from the preincubation mixture, 
[3H]cholestanyl ether (a lipid marker) was incorporated 
into the liposomes. A fraction of serum after centrifugation 
was counted in a scintillation counter to determine the total 
liposome removal by centrifugation. Over 95% of the total 
liposomes were removed by this method. The centrifuged 
serum fraction was then incubated with PS-containing 
liposomes labeled with ‘I1 In-DTPA-SA (testing lipo- 
somes). After a 10 min incubation at 37” C, the mixture 
was then diluted by adding 23 ml of saline prewarmed to 
37” C. Liver perfusion was then performed as described 
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Table 2 
Effect of preincubation of liposomes on the serum-mediated liver uptake 
of liposomes containing PS a 
Liposomes b Diameter ’ (nm) % Activity remaining 
Saline 100 
PC/Chol/PS 526 10 
PC/Chol/DPPG 509 20 
PC/Chol/PA 461 30 
PC/Chol/DCP 481 35 
a 1 ml of freshly collected bovine serum was incubated with either saline 
(200 /*I) or saline containing liposomes with different negatively charged 
phospholipids (2 pmol total lipids) for 10 min at 37” C. Liposomes in the 
mixture were removed by centrifugation. Liposome-treated serum (1 ml) 
was then incubated with PS-containing liposomes (0.6 pmol lipids in 60 
PI> “‘In-labeled) for 10 min at 37” C before dilution to a final volume of 
24 ml with saline. 20 ml of the mixture was then perfused through the 
liver as described in Materials and methods. The remaining activity in 
liposome-treated serum for PS-containing liposomes was measured and 
expressed as a percentage of liposome uptake for serum treated with 
saline. Data are presented as an average of two individual experiments. 
b The molar ratio of lipids in liposomes was 10:5:1. 
’ Average size of liposomes represents the results of unimodal analysis 
using submicron particle analyzer (Coulter N4SD). 
Materials and methods. As is shown in Table 2, over 60% 
of the serum activity for the testing liposomes was inhib- 
ited by each of the negatively charged liposomes tested. 
PS-containing liposomes (the same as the testing lipo- 
somes) showed the highest inhibition (90%) followed by 
liposomes containing PG (80% inhibition). Liposomes con- 
taining PA and DCP have a similar inhibition activity 
(- 65-70%). These results suggest that complement com- 
ponents may serve as opsonins for all negatively charged 
liposomes. In contrast, it also suggests that other types of 
negatively charged lipids, such as ganglioside GM, and 
phosphatidylinositol, which increases the liposome circula- 
tion time in mice may decrease the binding of components 
to the liposome surface. This prediction agrees well with 
the previous report that the GM, inhibits the activation of 
alternative pathway of the complement system [19]. 
4. Discussion 
The results presented here clearly demonstrate that the 
uptake of liposomes containing PS by the RES is mediated 
by serum opsonins, most likely by complement compo- 
nents. This conclusion was supported by several experi- 
mental results. First, minimum uptake of liposomes by the 
liver was observed in the absence of serum. An approx. 5 
to lo-fold increase was obtained when liposomes were 
preincubated with either blood or serum (Fig. 1). Second, 
the amount of liposomes taken up by the liver is related to 
the amount of serum present: high concentrations of serum 
generally gave higher uptake of liposomes (up to 33% 
serum in the perfusate, Fig. 2). Third, heat-treatment of 
serum at 56” C for 30 min to inactivate complement sys- 
tem, abolished the activity of serum in enhancing liposome 
uptake (Table 1). Finally, PS-containing liposomes inhibit 
the hemolysis of erythrocytes. These results suggest that 
PS on the surface of liposomes, sickled red blood cells or 
platelets serves as a signal to activate the complement 
system. It is the complement-derived opsonin bound to the 
membrane surface that triggers the recognition and clear- 
ance of these membrane vesicles by the RES. 
An important observation described in this report is the 
effect of liposome size on serum mediated liposome up- 
take by the liver. The larger the liposome diameter, the 
greater the serum effect on liposome uptake. One explana- 
tion for this result is that uptake depends on the density of 
opsonins on the liposome surface. For a given amount of 
serum, liposomes with small diameters and thus, larger 
surface area will have a lower density of opsonin on the 
membrane surface than those with large diameters. There- 
fore, the total amount of liposomes that have recognizable 
amounts of opsonin by the RES is lower for liposomes 
with small diameters than those with large diameters, 
resulting in a lower liposome uptake by the liver 
macrophages. The large liposomes which have relatively 
smaller surface areas will have more opsonins on the 
surface per liposome, resulting in a higher liver uptake. 
This explanation, although reasonable, can not explain the 
results in Fig. 3. If surface area is the key factor for 
opsonin binding, one would expect that small liposomes 
should inhibit the hemolysis of erythrocytes in the hemoly- 
sis assay more efficiently than the larger ones. In fact, 
larger liposomes inhibit the hemolysis of erythrocytes bet- 
ter than the small ones at any given concentration of 
liposomes. Thus, the possible mechanism for the size 
effect on serum mediated liposome uptake may relate to 
the efficiency of opsonization. The opsonization or binding 
of opsonins to liposomes may depend on the liposome 
diameter and the binding of opsonins to small liposomes 
may be less efficient than that of the large ones. Therefore, 
the number of opsonin molecules bound to the large 
liposomes will be greater than the number bound to small 
ones under experimental conditions. The work of Ha- 
rashima et al. [20] support this hypothesis. They demon- 
strated that small liposomes composed of hydrogenated- 
PC/Chol/DCP failed to activate the alternative pathway 
of the complement. The mechanism and the physiological 
importance of size dependent activation of complement are 
yet to be elucidated. It will be of interest to elucidate how 
liposome sizes are discriminated by the complement sys- 
tem. 
Comparison of liposome uptake by the liver in live 
animals versus a perfused liver preparation showed that the 
total liver uptake of liposomes was higher in live animals 
than in the perfused liver in the presence of either 66% 
whole blood or 33% serum (Fig. 1). This result is likely 
due to multiple passes of liposomes through the liver in the 
case of the live animals. In these experiments, blood 
circulation was continuous until the end of the 3 min. 
Liposomes entering the bloodstream at the beginning of 
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infusion would have multiple chances to be taken up by 
the liver had they escaped liver uptake on the first pass. 
Conversely in the perfusion experiments, blood circulation 
was terminated at the beginning of the perfusion, and 
therefore, liposomes passed through liver only once. 
While the evidence for the involvement of opsonins in 
liposome uptake is strong, the molecular identity of the 
opsonin(s) is not clear. As is shown in Tables 1 and 2, it 
seems that complement components may bind to all nega- 
tively charged liposomes. The binding affinity depends on 
the type of negative charge on the liposome surface. This 
conclusion agrees well with the reports by Harashima et al. 
[20] and others [18] that showed that liver uptake of 
liposomes composed of hydrogenated-PC/Chol/DCP is 
mediated by components in the alternative pathway of 
complement. It has also been reported that insertion of 
NBD-PG to the outer leaflet of red blood cell membrane 
resulted in a rapid removal of the cells from the circula- 
tion, but at a rate lower than that of RBC containing 
NBD-PS [21]. From the results presented and from others 
[20,22-241, it is reasonable to conclude that the clearance 
of liposomes by the RES is determined by liposome 
opsonization by complement components. The opsonin 
could bind to liposomes directly or be mediated by other 
serum factors such as antibodies. Opsonized liposomes 
could then trigger the binding and subsequent phagocytosis 
of liposomes by the macrophages in the RES. Liposomes 
containing glycolipids, such as ganglioside GM,, that in- 
hibits the binding of complement components to the lipo- 
some surface will have low affinity to the RES, and 
therefore have a prolonged circulation time. 
It has been reported that C3b became associated with 
liposomes when they wene administered into animals [25] 
and that removal of C3 from the serum by anti-C3 anti- 
body eliminates serum mediated liposome uptake by the 
perfused liver [20]. Furthermore, the known function of 
C3b in eliminating the blood born pathogens, such as 
bacteria and viruses [25], through C3 receptors makes it a 
strong candidate for opson.in. The role of C3b in mediating 
the liver uptake of PS-containing liposomes is under inves- 
tigation in our laboratory. 
The fact that 40% of the serum activity could be 
removed by dialysis with a molecular mass cut off of 
12-14 kDa suggests the involvement of multiple serum 
factors in liposome opsonization (Table 1). This conclu- 
sion agrees well with the earlier work of Kiwada et al. 1181 
where liposomes composed of hydrogenated egg PC, 
cholesterol and DCP (4:4:1, molar ratio) were used in liver 
uptake analysis. It is unknown at present what the factor(s) 
is and how it works in increasing liposome affinity for the 
liver. It is possible that the factor(s) with molecular mass 
of less than 12-14 kDa serves as a cofactor(s) for the 
activity of the opsonin. Removal of this factor(s) by dialy- 
sis may change the conformation of the opsonin such that 
binding to the liposomes is no longer possible. Alterna- 
tively, the factor(s) may involve in the process of liposome 
opsonization. It could be involved in the activation, bind- 
ing (Ken) or dissociation (K,,) of the opsonin to lipo- 
somes. Furthermore, the dialyzable factor(s) may work 
independently from the higher molecular weights serum 
components. In this case, the factor(s) must be heat labile 
since heat treatment (56” C, 30 min) of serum abolishes the 
total activity (Table 1). These possibilities plus many more 
are yet to be tested. 
It is interesting to point out that higher concentrations 
of serum actually decrease the liver uptake of PS-contain- 
ing liposomes (Fig. 2). Although it is not clear at the 
moment what the mechanism is, it seems that there are two 
systems in the serum working against each other in regard 
to liposome uptake by the liver. Such protection activity of 
serum against the activity of opsonin may suggest the 
existence of dysopsonins in the serum. Dysopsonin activity 
in serum has been demonstrated by Moghimi et al. [26] in 
a polystyrene micro sphere system. A possible explanation 
for the observation that the dysopsonin activity for PS-con- 
taining liposomes only appears at high concentrations of 
serum is that the concentration of dysopsonins in serum is 
low or alternatively, the binding affinity of dysopsonins for 
liposomes is low in comparison to that of opsonins. At low 
serum concentration, opsonin dominates the affinity of 
liposomes for the RES either because of higher concentra- 
tion or higher affinity to liposomes. At high concentrations 
of serum however, dysopsonin activity appears, resulting 
in a decrease of liposome affinity to the RES. It is worth 
noting that the dysopsonin activity can not surpass the 
activity of opsonin in the case of PS-containing liposomes. 
For example, increase of serum concentration from 50% to 
60% did not result in a further decrease of liposome uptake 
by the liver (Fig. 2A). This suggests that the affinity of 
liposomes to the RES in vivo is likely determined by two 
opposite processes. The mechanism of this process awaits 
elucidation. 
In conclusion, PS-mediated liposome uptake by the 
macrophages in the liver is a result of opsonization by 
complement components. PS, itself, does not serve as a 
direct signal to trigger the recognition and phagocytosis by 
the macrophages in the RES in rats. Opsonization effi- 
ciency depends on the liposome diameter. Although we 
have not determined the detailed mechanism of the op- 
sonization and the factors involved in the process, it does 
appear that the complement system that is involved in the 
fight against invasion of microbes by our body may also 
have the same function in removal of liposomes, micro- 
spheres, emulsion particles and aged red blood cells. 
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